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Introduction {#sec1}
============

Human peripheral blood γδ T cells are dominated from an early age by Vγ9Vδ2 lymphocytes ([@bib22]), an innate-like subset that features a predominant effector status, allowing potent cytokine production and cytotoxic capability that is linked to a relatively restricted T cell receptor (TCR) repertoire ([@bib4], [@bib5]). Vγ9Vδ2 T cells universally respond in a TCR-dependent fashion to non-peptidic pyrophosphate compounds (phosphoantigens \[P-Ag\]). These include the microbially derived compound (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) ([@bib19]), which is generated by the non-mevalonate isoprenoid synthetic pathway and is a highly potent activator of Vγ9Vδ2 T cells. In addition, host-cell-derived isoprenyl pyrophosphate (IPP) can act as a P-Ag and stimulate Vγ9Vδ2 T cell responses. IPP levels are elevated in some cancer cells and can also be therapeutically increased in target cells via aminobisphosphonate drugs that inhibit IPP catabolism, such as Zoledronate (Zol) ([@bib9], [@bib15]).

Vγ9Vδ2-mediated P-Ag sensing requires cell-cell contact ([@bib18]) and depends on both Vγ and Vδ chains, with evidence for involvement of multiple complementarity-determining region (CDR) loops ([@bib35]). An essential prerequisite for P-Ag sensing is target-cell expression of butyrophilin (BTN) 3A1 ([@bib11]), a member of a multi-gene family encoded on chromosome (Chr) 6. BTNs and butyrophilin-like (BTNL) molecules are structurally related to the B7 family of costimulatory molecules, comprising two extracellular immunoglobulin (Ig)-like domains, a transmembrane region, and a cytoplasmic tail that often contains a B30.2 domain ([@bib23]). In addition to immunomodulatory effects on antigen-presenting cells and conventional αβ T cells, several BTN and/or BTNL family members are emerging as playing critical roles in γδ T cell development and activation ([@bib1], [@bib6], [@bib11], [@bib17], [@bib33], [@bib37]). Although the extracellular domain of BTN3A1 was initially reported to present P-Ag and directly bind the Vγ9Vδ2 TCR ([@bib34]), other studies have challenged both of these findings and instead support the concept that BTN3A1 senses P-Ag directly. These data include robust evidence for P-Ag binding to the intracellular B30.2 domain of BTN3A1 and for a P-Ag-induced conformational change ([@bib20], [@bib27], [@bib29]). In addition, the importance of BTN3A2 and/or BTN3A3 co-expression alongside BTN3A1 for optimal P-Ag sensing has been highlighted, as well as the potential of these family members to heterodimerize with BTN3A1 in an IgC-dependent manner ([@bib33]).

Vγ9Vδ2 T cells emerged with the appearance of placental mammals and have been retained in both primates and species as diverse as dolphin (*Tursiops truncatus*) and alpaca (*Vicugna pacos*) ([@bib7], [@bib13]). Of note, the alpaca is the only non-primate species to date with proven P-Ag reactivity of Vγ9Vδ2 T cells and P-Ag binding to BTN3 demonstrated ([@bib8]). In contrast, rodents lack BTN3, Vδ2, and Vγ9 homologs ([@bib13]). Consistent with an important role in host immunity, Vγ9Vδ2 T cell expansion and activation is observed in a variety of microbial infections ([@bib19]). Furthermore, attempts to therapeutically harness the human γδ T cell compartment have hitherto focused predominantly on the Vγ9Vδ2 subset in the context of both specific infections ([@bib30]) and cancer ([@bib15], [@bib31]). From this perspective, the mechanism underpinning Vγ9Vδ2 T cell activation has been a focus of strong interest.

Our previous studies have established that BTN3A1 is necessary but not sufficient for P-Ag sensing and indicated the existence of an additional putative Chr-6-encoded factor that synergized with BTN3A1 to stimulate P-Ag-mediated responses ([@bib24]), which we subsequently coined "Factor X" ([@bib12]). Here, we set out to identify Factor X using a radiation hybrid approach. We identified BTN2A1 as this critical factor and showed it interacts directly with the Vγ9Vδ2 TCR to potentiate P-Ag-dependent recognition, highlighting its role in a "composite ligand" model of Vγ9Vδ2 T cell recognition.

Results {#sec2}
=======

Radiation Hybrids Identify BTN2A1 as Essential for P-Ag Sensing {#sec2.1}
---------------------------------------------------------------

We showed previously that a T cell hybridoma expressing the Vγ9Vδ2 MOP TCR produced interleukin (IL)-2 in co-culture with BTN3A1-transduced Chinese hamster ovary (CHO) cells incubated with the anti-BTN3A1 monoclonal antibody (mAb) 20.1 but exhibited a complete lack of response to HMBPP or Zol ([@bib24], [@bib32]). In contrast, HMBPP and Zol sensitivity was restored in co-cultures with human-rodent hybrid cells, including CHO cells containing a single human Chr 6 (CHO Chr6 cells). Based on this observation, we postulated the existence of a Factor X encoded on Chr 6, which in addition to BTN3A1 is mandatory for P-Ag-mediated γδ T cell stimulation ([@bib24]).

To identify Factor X, we used an unbiased genome-based approach involving generation of radiation hybrids between CHO-Chr 6 cells and BTN3A1-transduced hypoxanthine-aminopterin-thymidine (HAT)-sensitive rodent fusion partners and subsequent analysis of their capacity to stimulate P-Ag sensing by Vγ9Vδ2 T cells ([Figure 1](#fig1){ref-type="fig"}A). We postulated that comparison of the human gene products transcribed in stimulatory radiation hybrids would allow mapping of the gene(s), which alongside BTN3A1 are mandatory for PAg-mediated stimulation.Figure 1Identification of BTN2A1 as Factor X(A) Radiation hybrid approach to generate and identify rodent cell-fusion hybrids incorporating portions of human chromosome (Chr) 6 that permit P-Ag sensitization.(B) RNA-seq analysis of prioritized clones generated from fusion with A23 or BW cells. Values for less than three transcripts are merged with the x axis.(C) Arrangement of BTN gene cluster on Chr 6 extracted from genome data viewer GRCh38.p13 (GCF_000001405.39).(D) Production of IFNγ from polyclonal Vγ9Vδ2 T cell lines in response to Zol-treated WT or *BTN2*^−/−^ 293T cells. Error bars represent standard deviation for three independent experiments. ^∗∗^p \< 0.005.(E) Production of IL-2 from TCR-MOP transductants in response to HMBPP-treated WT, *BTN2*^−/−^, *BTN2A1*^−/−^, and *BTN2A2*^−/−^ 293T cells.(F) Production of IL-2 from TCR-MOP transductants in response to 20.1 mAb-treated WT, *BTN2*^−/−^, *BTN2A1*^−/−^, and *BTN2A2*^−/−^ 293T cells.In (E) and (F), the different colors indicate results from two independent experiments. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We fused CHO-Chr6 cells separately with two HAT-sensitive fusion partners---first BTN3A1-transduced A23 hamster cells and second BTN3A1-transduced mouse BW cells ([STAR Methods](#sec4){ref-type="sec"}) ([@bib28]); resulting radiation hybrids were assessed for P-Ag-dependent activation of TCR-MOP transductants and positive candidates cloned by limiting dilution. In some cases, these clones were used as donor cells for further fusions. A final selection of clones ([Figure S1](#mmc1){ref-type="supplementary-material"}A) were subjected to RNA sequencing (RNA-seq) analysis ([Figure 1](#fig1){ref-type="fig"}B; [STAR Methods](#sec4){ref-type="sec"}) alongside CHO-Chr6 cells and rodent fusion partner cells as positive and negative controls, respectively.

A region of ∼580 kB of Chr 6 permitting P-Ag-mediated stimulation by the radiation hybrids was identified ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B). Analysis of candidate genes within this region revealed that the only transmembrane molecules among the expressed human genes were the major histocompatibility complex (MHC)-class-I-like iron transporter *HFE*, the *BTN3A1* gene already transduced into rodent fusion partners, *BTN3A2*, *BTN3A3*, and *BTN2A1* and *BTN2A2*. Since we knew that expression of all three BTN3 genes was insufficient for reconstitution of the P-Ag response (D.P., A.S.F., M.M.K., and T.H., unpublished data), *BTN2A1* and *BTN2A2*, which to date have been discussed mainly for their immunomodulatory properties ([@bib23]), emerged as the prime candidates for encoding Factor X.

We then tested the effects on P-Ag-dependent stimulation of Vγ9Vδ2 lymphocytes by human 293T cells after CRISPR-Cas9-mediated inactivation of either both BTN2 genes (*BTN2*^−/−^) or *BTN2A1* (*BTN2A1*^−/−^) or *BTN2A2* alone (*BTN2A2*^−/−^). Inactivation of both BTN2 genes completely abolished interferon (IFN)γ production by polyclonal Vγ9Vδ2 T cell lines in response to Zol pulsed cells ([Figure 1](#fig1){ref-type="fig"}D). Crucially, both *BTN2*^−/−^ and *BTN2A1*^−/−^ exhibited a complete loss of IL-2 production by TCR-MOP cells in response to either HMBPP ([Figure 1](#fig1){ref-type="fig"}E) or 20.1 mAb ([Figure 1](#fig1){ref-type="fig"}F), whereas responses to *BTN2A2*^−/−^ were similar to wild-type (WT) 293T cells ([Figures 1](#fig1){ref-type="fig"}E and 1F). These experiments strongly suggested that alongside BTN3A1, BTN2A1 was critical for P-Ag sensing.

BTN2A1 and BTN3A1 Are Sufficient to Potentiate Vγ9Vδ2-Mediated P-Ag Sensing {#sec2.2}
---------------------------------------------------------------------------

To address whether *BTN2A1* was sufficient alongside *BTN3A1* to reconstitute P-Ag sensitization in rodent cells, we transduced either one or both genes into both CD80^+^ BW and CD80^+^ CHO cells ([Figures 2](#fig2){ref-type="fig"}A--2C) and tested their ability to induce IL-2 production from TCR-MOP cells following incubation with HMBPP. In both cases, whereas transduction of BTN3A1 alone resulted in negligible responses, transduction of both BTN2A1 and BTN3A1 permitted a robust, HMBPP-dose-dependent IL-2 response, confirming their sufficiency for P-Ag sensitization ([Figures 2](#fig2){ref-type="fig"}B and 2C). Interestingly, transduction of BTN2A1 alone resulted in a weak, HMBPP-dose-independent basal response to both cell lines ([Figures 2](#fig2){ref-type="fig"}B and 2C).Figure 2BTN2A1 and BTN3A1 Synergize to Potentiate P-Ag Sensing in Rodent Cells(A) Expression of BTN2A1, BTN3A1, or both genes in transduced BW cells.(B) Production of IL-2 by TCR-MOP transductants in response to HMBPP-treated CD80^+^ BW cells transduced to express BTN2A1, BTN3A1, both, or untransduced controls. Percentage activation is normalized against the maximum response obtained from CD80^+^ CHO cells expressing both BTN2A1 and BTN3A1 in the presence of 10 μM HMBPP.(C) Production of IL-2 from TCR-MOP transductants in response to HMBPP-treated CD80^+^ CHO cells transduced with either BTN2A1, BTN3A1, both genes, or untransduced controls, with responses normalized as in (B).Error bars in (B) and (C) represent standard deviation for three independent experiments. Differences between untransduced and BTN2-transduced cells were significant (p \< 0.05), as were those between the BTN2A1-transductant and BTN2A1+BTN3A1-transductant in the presence of HMBPP.(D) MOP-TCR tetramer staining of transduced BW cells.(E) Staining of transduced 293T cells with Vγ9Vδ2 TCRs.(F) MOP-TCR tetramer staining or anti-BTN2A1 mAb staining of BTN2A1 and BTN3A1-transduced CD80^+^ BW cells versus untransduced controls in the presence and absence of Zol.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To assess whether BTN2A1 surface expression was able to support binding to the Vγ9Vδ2 TCR, we generated Vγ9Vδ2 TCR tetramers and used them to stain transduced BW and 293T cells ([Figures 2](#fig2){ref-type="fig"}D and 2E). BTN2A1 expression on transduced BW and 293T cells was sufficient to enable staining by Vγ9Vδ2 MOP-TCR tetramer ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S2](#mmc1){ref-type="supplementary-material"}A), supporting the idea that BTN2A1 may be a direct TCR ligand; moreover, all Vγ9Vδ2 TCR tetramers tested stained BTN2A1-transduced cells ([Figure 2](#fig2){ref-type="fig"}E). Consistent with the minimal basal BTN2A1-dependent IL-2 response observed in the absence of P-Ag or BTN3A1 ([Figures 2](#fig2){ref-type="fig"}A and 2B), BTN3A1 co-expression was not required for BTN2A1-mediated tetramer staining ([Figure 2](#fig2){ref-type="fig"}D), nor was exposure to Zol necessary for tetramer staining ([Figure 2](#fig2){ref-type="fig"}F). This suggested BTN2A1 might be an independent ligand for the Vγ9Vδ2 TCR, the activatory potential of which is critically augmented in a BTN3A1- and P-Ag-dependent manner.

We then investigated why BTN2A2, which shares close 88% sequence identity with BTN2A1 in its extracellular region, was unable to potentiate P-Ag sensing alongside BTN3A1. BTN2A2-293T transductants did not support tetramer staining ([Figure S2](#mmc1){ref-type="supplementary-material"}A), suggesting BTN2A2 might not be able to recognize the Vγ9Vδ2 TCR. However, one major caveat was the considerably lower surface expression of BTN2A2 relative to BTN2A1 in 293T transductants ([Figure S2](#mmc1){ref-type="supplementary-material"}B), which could also explain this observation.

BTN2A1 IgV Domain Directly Binds Germline-Encoded Regions of Vγ9^+^ TCRs {#sec2.3}
------------------------------------------------------------------------

To establish whether BTN2A1 acted as a direct ligand for the Vγ9Vδ2 TCR, we expressed the membrane-distal domain of the BTN2A1 ectodomain and tested direct binding to recombinant Vγ9Vδ2 TCR using surface plasmon resonance (SPR). Injection of BTN2A1 IgV produced substantially enhanced signals over surfaces with immobilized Vγ9Vδ2 TCR relative to Vγ4Vδ5 and Vγ2Vδ1 TCRs or control streptavidin surfaces, indicating specific binding ([Figure 3](#fig3){ref-type="fig"}A). Equilibrium affinity measurements of BTN2A1 IgV binding to the G115 and MOP Vγ9Vδ2 TCRs established K~d~ values of 45.4 μM (n = 9) and 49.9 μM (n = 8), respectively ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Direct BTN2A1 Binding to Germline-Encoded Regions of Vγ9 Is Essential for P-Ag Sensing(A) (Top panel) Injection of BTN2A1 IgV (25 μM) over surfaces with immobilized Vγ9Vδ2 TCR (2,457 resonance units (RU)) and control surfaces comprising Vγ4Vδ5 TCR (2,351 RU), Vγ2Vδ1 TCR (1,800 RU), or streptavidin alone. Notably, signals over streptavidin alone and control TCR surfaces are equivalent. (Bottom panel) Injection of BTN2A1 IgV (24 μM) over surfaces with immobilized G115 (Vγ9Vδ2; 3,109 RU), MOP (Vγ9Vδ2; 3,108 RU), and Vγ9Vδ1 (2,774 RU) TCRs and LES TCR control (Vγ4Vδ5; 2,885 RU).(B) Equilibrium affinity measurements and Scatchard analysis (inset) of BTN2A1 IgV binding to the G115 (K~d~ = 39.5 μM) and MOP (K~d~ = 48.4 μM) Vγ9Vδ2 TCRs and Vγ9Vδ1TCR (K~d~ = 47.9 μM).Data in (A) and (B) are representative of eight to nine independent experiments.(C) Model of the BTN2A1-Vγ9 interaction mode based on the proposed BTNL3-Vγ4 interaction, with expanded panel showing potential contacts at the Vγ9-BTN2A1 IgV interface.(D) Effects of seven alanine substitutions in proposed BTN2A1 interface residues on Vγ9Vδ2 TCR interaction, indicating affinity of mutant BTN2A1 relative to WT BTN2A1 calculated in the same experiment. Data shown are representative of two independent experiments.(E) Effects of BTN2A1 R124A and R124E mutations on IL-2 production by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1 expressing CD80^+^ CHO cells.(F) Predicted involvement of Vγ9 HV4 and CDR2 residues in BTN2A1 interaction.(G) Effects of Vγ9-E70 mutation (HV4) on IL-2 production by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1 expressing CD80^+^ CHO cells.(H) Effects of mutations in Vδ2 CDR2 (R51A) or a deletion in CDR3 (ΔCDR3) on IL-2 production by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1 expressing CD80^+^ CHO cells.In (E), (G) and (H), error bars indicate standard deviation for three independent stimulation experiments. Percentage activation is normalized against the maximum response obtained from CHO cells expressing both BTN2A1 and BTN3A1 in the presence of 1 μM HMBPP. Differences between WT and mutants in (E), (G), and (H) were significant, except for TCR-MOP E70A at 1 μM. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Unexpectedly, experiments also indicated clear binding of BTN2A1 IgV to a Vγ9Vδ1 TCR, which was derived from the non-P-Ag reactive Vδ1^+^ T cell subset ([@bib10]) ([Figure 3](#fig3){ref-type="fig"}A); consistent with this, Vγ9Vδ1 TCR tetramers specifically stained BTN2A1-transduced 293T cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Taking into account the highly similar affinity (K~d~ 46.6μM \[n = 8\]) of the BTN2A1-Vγ9Vδ1 TCR interaction ([Figure 3](#fig3){ref-type="fig"}B) and the radically divergent CDR3γ expressed by this TCR relative to Vγ9Vδ2 TCRs ([Figure S3](#mmc1){ref-type="supplementary-material"}A), these results strongly suggested the BTN2A1-Vγ9Vδ2 interaction focused on germline encoded regions of the Vγ9 IgV domain. This implied that the BTN2A1-Vγ9Vδ2 interaction might be analogous to BTNL3 binding to human Vγ4^+^ TCRs ([@bib17], [@bib37]), which is similarly focused on germline-encoded regions of the Vγ4 chain and allowed us to model BTN2A1-Vγ9 interaction based on the proposed BTNL3-Vγ4 interaction mode ([Figure 3](#fig3){ref-type="fig"}C).

An initial homology model suggested strong feasibility of a similar interaction mode and highlighted seven amino acids on the face of the BTN2A1 IgV domain incorporating the C, C\', F and G β strands (CFG face), equivalent to the region of BTNL3 IgV domain involved in binding Vγ4, as candidates for alanine mutation ([Figure 3](#fig3){ref-type="fig"}C). Individual BTN2A1 alanine mutants were generated for these seven residues. Of these, four completely abrogated BTN2A1 binding to Vγ9Vδ2 TCR (R65A, R124A, Y126A, E135A), a fifth marginally decreased affinity (K79A), Y133A did not affect binding, and S72A increased affinity (K~d~ 10--15 μM) ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). These results allowed generation of an improved, mutationally informed model of BTN2A1/Vγ9 interaction using the high-ambiguity driven protein-protein DOCKing (HADDOCK) software, analysis of which outlined a molecular rationale for the effect of each mutation ([Figure S3](#mmc1){ref-type="supplementary-material"}C; [STAR Methods](#sec4){ref-type="sec"}). Based on comparison of the BTN2A2 IgV sequence ([Figure S3](#mmc1){ref-type="supplementary-material"}D) and a BTN2A2 homology model ([Figure S3](#mmc1){ref-type="supplementary-material"}E) in the context of this BTN2A1 model, we predicted that BTN2A2 IgV would also be competent for Vγ9 TCR binding, which was subsequently confirmed using SPR for both Vγ9Vδ2 TCRs ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G) and a Vγ9Vδ1 TCR ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H), which indicated a similar affinity to BTN2A1 (K~d~ 39--50 μM \[n = 3\]).

To assess the dependence of the functional activity of BTN2A1 on TCR binding, we transduced CHO-BTN3A1 cells with the BTN2A1 R124A mutation shown to abrogate Vγ9^+^ TCR binding (and also a BTN2A1 R124E charge-reversal mutant) and assessed effects on Vγ9Vδ2-mediated P-Ag response. Although permissive for cell-surface BTN2A1 expression ([Figure S3](#mmc1){ref-type="supplementary-material"}I), both mutations completely abrogated both P-Ag-dependent IL-2 production and basal P-Ag-independent BTN2A1-mediated responses ([Figure 3](#fig3){ref-type="fig"}E). Furthermore, BTN2A1 R65A and Y126A mutations that eliminated Vγ9^+^ TCR-BTN2A1 interaction also abrogated P-Ag-dependent and independent responses ([Figure S3](#mmc1){ref-type="supplementary-material"}J). However, although mCherry reporter signal was detected for each construct, it must be noted that these mutant proteins could not be detected using the anti-BTN2A1 mAb ([Figures S3](#mmc1){ref-type="supplementary-material"}K and S3L). We therefore could not exclude the possibility that these mutations affected cell-surface expression, although alternatively, they could be important components of the anti-BTN2A1 mAb epitope.

The mutationally guided model also indicated involvement of multiple TCR residues in the HV4 (including E70, I74, E76, T77, T79) and CDR2 (G56, T57, V58) loops of the Vγ9 IgV domain in BTN2A1 interaction, regions also critical for BTNL3-Vγ4 interaction ([@bib37]) ([Figure 3](#fig3){ref-type="fig"}F). Consistent with this, Vγ9Vδ2-expressing hybridomas bearing mutations at TCRγ HV4 E70 eliminated BTN2A1-dependent P-Ag-independent IL-2 production and substantially affected TCR-dependent P-Ag responses, with E70K exhibiting severely reduced activation potential ([Figure 3](#fig3){ref-type="fig"}G). Although the BTN2A1-Vγ9 model was supported by our BIAcore data ([Figure 3](#fig3){ref-type="fig"}A) in indicating no role for Vδ in BTN2A1 recognition, we sought to establish whether BTN2A1-dependent P-Ag sensing was nevertheless affected by Vδ2 CDR loops by generating TCR hybridomas bearing either a CDR3 deletion of TCR-MOP (ΔCDR3) ([Figure S3](#mmc1){ref-type="supplementary-material"}B) or a R51A substitution in CDR2 ([@bib16]). Each mutation abolished both P-Ag-dependent IL-2 responses and BTN2A1-dependent P-Ag-independent basal responses ([Figure 3](#fig3){ref-type="fig"}H).

Collectively, these findings established that Vγ9Vδ2 TCR binds BTN2A1 IgV via a binding mode that closely mimics that of Vγ4 TCR for BTNL3 and that this binding is essential for P-Ag sensing but occurs alongside parallel and essential Vδ2 CDR-mediated binding events.

BTN2A1 Can Form Disulphide-like Homodimers at the Cell Surface {#sec2.4}
--------------------------------------------------------------

BTN and BTNL molecules have been shown to form either homo- or heterodimers ([@bib21], [@bib33]). To investigate BTN2A1's propensity for dimer formation, we carried out homology modeling of BTN2A1 IgV-C ([Figures 4](#fig4){ref-type="fig"}A and 4B) based on superposition of BTN2A1 onto the structure of the BTN3A1 V-shaped homodimer ([@bib21]). Inspection of the model confirmed a viable IgC-IgC homodimer interface driven by main-chain-main-chain hydrogen bonding interactions supplemented by side-chain-dependent hydrophobic contacts; these were predicted to be broadly equivalent to those of BTN3A1 IgC-IgC, albeit with increased interchain hydrophobic contacts in BTN2A1 (M153, F235) versus BTN3A1 (V154, S236), indicating a strong potential for non-covalent dimer formation ([Figure S4](#mmc1){ref-type="supplementary-material"}A); in addition, further analyses indicated a similar potential for heterodimer formation with other members of the BTN family ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 4BTN2A1 Forms Disulphide-Linked Homodimers at the Cell Surface(A) Homology model of BTN2A1 homodimer.(B) C-terminal region of BTN2A1 homology model indicating close proximity of Cys residues.(C) Non-reducing (NR) or reducing (R) SDS-PAGE analysis of CHO-cell expressed BTN2A1 and BTN2A2 protein.(D) Effects of BTN2A1C247W mutation on IL-2 production by TCR-MOP in response to HMBPP-treated CD80^+^ CHO cells expressing BTN2A1 and BTN3A1. Error bars indicate standard deviation for three independent stimulation experiments. Percentage activation is normalized against the maximum response obtained from CHO cells expressing both BTN2A1 and BTN3A1 in the presence of 1 μM HMBPP.(E) Model of Vγ9Vδ2-BTN2A1 interaction incorporating BTN2A1 homodimer formation, and bilateral Vγ9Vδ2 interaction with BTN2A1 IgV domain.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Interestingly, the BTN2A1 IgV-C model also highlighted close proximity of extracellular membrane-proximal cysteine residue (C247) with its equivalent residue in the opposing monomer ([Figure 4](#fig4){ref-type="fig"}B), suggesting that the homodimer might be stabilized additionally by an interchain disulphide bond; of note, this cysteine is lacking in all other BTN and BTNL molecules ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Indeed, SDS-PAGE and immunoblot-streptavidin detection of BTN2A1 under reducing and non-reducing conditions confirmed that the overwhelming majority of cell surface BTN2A1 was present as a disulphide-bonded dimer ([Figure 4](#fig4){ref-type="fig"}C), even in the presence of BTN3A1 and in the presence and absence of Zol ([Figure S4](#mmc1){ref-type="supplementary-material"}D), consistent with the BTN2A1 homodimer model ([Figures 4](#fig4){ref-type="fig"}A and 4B). However, transduction of BTN2A1 bearing a C247W mutation did not affect P-Ag-dependent or P-Ag-independent basal IL-2 production ([Figure 4](#fig4){ref-type="fig"}D); therefore, any disulphide stabilization may be redundant owing to strong existing non-covalent homodimer potential. In contrast, BTN2A2, which lacks this cysteine residue, did not form disulphide-linked dimers ([Figure 4](#fig4){ref-type="fig"}C), but analogous structural modeling indicated equivalent propensity for non-covalent IgC-IgC-mediated homodimer formation ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

Finally, by combining our HADDOCK-derived model of Vγ9Vδ2/BTN2A1 interaction ([Figure S3](#mmc1){ref-type="supplementary-material"}B) with our BTN3A1-based homology model of the BTN2A1 homodimer ([Figure 4](#fig4){ref-type="fig"}A), we were able to envisage how BTN2A1 recognition might take place at the cell surface ([Figure 4](#fig4){ref-type="fig"}E). Notably, the Vγ9Vδ2 TCR-BTN2A1 interaction mode can in principle allow clustering of two TCRs for each BTN2A1 homodimer, each with somatically recombined CDR3 loops implicated in P-Ag sensing oriented directly toward the target cell surface.

BTN2A1 Is Closely Associated with BTN3A1 at the Cell Surface {#sec2.5}
------------------------------------------------------------

To assess whether BTN2A1 and BTN3A1 were associated with each other at the cell surface either before or after P-Ag exposure, a membrane-impermeable amine-reactive cross-linker incorporating a 16Å spacer was used to cross-link proteins on the surface of CHO transductants co-expressing C-terminally HA-tagged BTN2A1 (BTN2A1-HA) and a N-terminally FLAG-tagged BTN3A1 (FLAG-BTN3A1). Immunoprecipitation (IP) using anti-HA beads or 20.1 mAb and subsequent anti-FLAG western blot (WB) was used to detect cross-linked BTN2A1-BTN3A1 species ([Figure 5](#fig5){ref-type="fig"}).Figure 5Cell-Surface Association of BTN2A1 and BTN3A1 Proteins(A) Anti-BTN2A1-HA immunoprecipitation, combined with anti-BTN3A1-FLAG western blot detection, following cell-surface cross-linking of CHO cells expressing BTN2A1-HA, FLAG-BTN3A1, or both.(B) Anti-BTN3A1 IP (20.1 mAb) of the same lysate combined with anti-BTN3A1-FLAG detection.For (A) and (B), likely monomeric or oligomeric species corresponding to appropriate molecular weight bands are indicated on the right-hand side. Data are representative of four independent experiments.(C) NMR chemical-shift perturbations (CSPs) in selected residues in ^1^H-^15^N-labeled BTN3A1 IgV (100 μM) following addition of BTN2A1 IgV (100 μM).(D) Graph of chemical shift versus residue number in BTN3A1 IgV. Threshold levels for significant CSPs are indicated by horizontal lines.(E) Mapping of residues whose amide resonances undergo CSPs on the surface of BTN3A1 IgV domain, showing clustering in the CFG face of the domain. Residues are colored in relation to the size of their CSPs, using the thresholds indicated in (D).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Following IP of BTN2A1-HA using anti-HA beads and subsequent WB detection of FLAG-BTN3A1 under reducing conditions using an anti-FLAG antibody, two discrete bands were detected that considerably exceeded the size of either BTN2A1 or BTN3A1 monomers (observed molecular weights \[MWs\] ∼55k Da, FLAG-BTN3A1; ∼70 kDa, BTN2A1-HA) ([Figure 5](#fig5){ref-type="fig"}A); each was only detected in the presence of cross-linker. One band was ∼130 kDa, equivalent to cross-linking of a single BTN2A1 monomer and BTN3A1 monomer (125 kDa expected MW). A second represented a considerably larger cross-linked species (exceeding the weight of the 180 kDa marker), most likely equivalent to one BTN2A1 homodimer and one BTN3A1 homodimer (∼250 kDa) ([Figure 5](#fig5){ref-type="fig"}A). In addition, both bands were also detected when the BTN3A1-specific mAb 20.1 was used for the initial immunoprecipitation step ([Figure 5](#fig5){ref-type="fig"}B), including when polyclonal anti-BTN2A1 antibody was used for WB detection ([Figure S5](#mmc1){ref-type="supplementary-material"}). Incubation of CHO transductants with Zol was also used to assess if the presence of cross-linked BTN2A1-BTN3A1 species was dependent upon P-Ag levels ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}A). Of note, both higher-MW BTN2A1-BTN3A1 bands were detected in the presence and absence of Zol ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}A), indicating BTN2A1 association with BTN3A1 occurs constitutively.

To investigate whether BTN2A1-BTN3A1 association involved IgV-IgV domain interactions, we expressed and purified ^1^H-^15^N-labeled BTN3A1 IgV in *E. coli* and performed ^1^H-^15^N heteronuclear single quantum coherence (HSQC) spectroscopy in the absence and presence of an equimolar amount of naturally labeled *E. coli*-expressed BTN2A1 IgV ([Figures 5](#fig5){ref-type="fig"}C--5E and [S5](#mmc1){ref-type="supplementary-material"}B). Analyses were facilitated by our previous assignment of all amide residues of the BTN3A1 IgV domain ([@bib27]) and demonstrated small but significant chemical-shift perturbations (CSPs) in numerous BTN3A1 residues in the presence of BTN2A1 IgV ([Figures 5](#fig5){ref-type="fig"}C and 5D), indicating direct interaction. Mapping these CSPs onto the BTN3A1 IgV domain structure indicated the majority of these residues clustered around the CFG face of the BTN3A1 domain ([Figure 5](#fig5){ref-type="fig"}E). Importantly, this region of BTN3A1 or BTN3A2 (which share an identical IgV domain) has been highlighted as critical for P-Ag sensitization ([@bib37]), including specifically Y127, K136, and R73; notably, we show that both Y127 and K136 displayed detectable chemical shifts upon BTN2A1 binding, as did S70, S71, and Q74. In contrast, no CSPs were detected in similar experiments using ^1^H-^15^N-labeled BTN3A1 following addition of a control BTN family IgV domain (unlabeled BTNL3; [@bib37]) ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). These results indicate that IgV-IgV domain interactions involving the CFG face of BTN3A1 or BTN3A2 contribute to BTN2A1-BTN3A1 association.

Discussion {#sec3}
==========

Here, we identified BTN2A1 as Factor X via a radiation hybrid approach that highlighted a critical ∼580 kb region of Chr 6, in which we probed candidate genes that were retained in species that bear Vγ9Vδ2 T cells but were missing or non-conserved in mouse. BTN2A1-transduced rodent cells were specifically stained by Vγ9Vδ2 TCR tetramers, and crucially, BTN2A1 exhibited strong functional synergy with BTN3A1, restoring P-Ag sensing following co-transduction into mouse cells. Moreover, using SPR, we were able to demonstrate specific binding of BTN2A1 IgV domain to Vγ9Vδ2 TCRs. In addition, target cells transduced with BTN2A1 molecules incorporating single amino acid mutations that eliminated Vγ9Vδ2 TCR binding in SPR experiments failed to stimulate P-Ag-specific effector responses in Vγ9Vδ2 T cells. These findings not only establish BTN2A1 as the putative Factor X co-factor in P-Ag sensing but also highlight that its role as a direct ligand for the Vγ9Vδ2 TCR is essential to its ability to potentiate P-Ag sensing. Of note, Rigau et al. recently also identified BTN2A1 as a critical mediator of P-Ag sensing and a direct ligand for Vγ9^+^ TCRs using a TCR-tetramer staining and CRISPR-screen approach ([@bib25]).

Our results highlight the potential of radiation hybrids as a test system for identification of genomic regions controlling cellular phenotypes and function. The relatively simple screening scheme for identification of these regions by comparison of radiation hybrid transcriptomes facilitates the generation of custom-made radiation hybrids, which is an advantage over genetically defined radiation hybrid panels ([@bib26]). Moreover, enabling rodent cells with capacity for P-Ag sensitization will not only help to understand Vγ9Vδ2 T cell function *in vitro* but also aid in establishing much-needed small animal models for the study of P-Ag-reactive cells. The De Libero group had shown ([@bib14]) that Vγ9Vδ2 TCR transgenic mouse cells exhibit a block in thymic maturation, which can be overcome by administration of anti-CD3 antibody, suggesting a positive selection signal provided by species-specific molecules. We hypothesize that BTN2A1 and/or BTN3A1 are such molecules and aim to test whether *in vivo* expression of BTN2A1 and/or BTN3A1 enables Vγ9Vδ2 T cell maturation. If established, such a model would allow the determinants controlling γδ T cell responses and functionality in the emerging Vγ9Vδ2 T cell compartment to be studied and importantly would allow for development of small animal models for harnessing Vγ9Vδ2 T cells in pathological conditions such as cancer and infections with Vγ9Vδ2 T cell activating pathogens.

Establishment of direct binding experiments enabled us to probe the interaction mode of BTN2A1 with the Vγ9Vδ2 TCR. Our finding that TCR binding to BTN2A1 is solely dependent upon the TCR Vγ9 chain is entirely consistent with the finding that Vδ2 T cells expressing alternative non-Vγ9 Vγ regions are both insensitive to P-Ag and also adopt an adaptive-like biology fundamentally distinct from the innate-like features of Vγ9Vδ2 T cells ([@bib3]). However, it was initially surprising, given that previous studies have highlighted the importance of multiple CDRs of both Vγ9 and Vδ2 TCR chains (including CDR3γ and CDR3δ) to Vγ9Vδ2-mediated P-Ag sensing ([@bib35]); moreover, our mutagenesis studies provided additional confirmation of the importance of CDR3δ and CDR2δ residues for BTN2A1-stimulated P-Ag sensing. Furthermore, the exclusive focus of BTN2A1 on Vγ9 raised the question of whether the Vγ9Vδ2-BTN2A1 interaction mode was related to that of intestinal Vγ4 T cell recognition of BTNL3.8 ([@bib37]), which involves germline-encoded CDR2 and HV4 regions of the Vγ4 TCR chain and the CFG face of the BTNL3 IgV domain. Modeling and mutagenesis approaches confirmed a fundamental similarity with this binding mode, indicating both CDR2 and HV4 regions of the Vγ9 TCR chain, and residues in the CFG face of BTN2A1 were critical for recognition. These results highlight clear evolutionary conservation of the "superantigen-like" BTN or BTNL-γδ TCR interaction mode across different anatomical sites, which will no doubt be elucidated further by future structural analyses.

The oligomerisation state and interaction partners of BTN2A1 on the target cell surface are likely important factors in its mode of action. Specifically, we show that cell surface BTN2A1 is comprised predominantly of homodimers in transduced rodent cells and 293T cells. This is consistent with structural work that highlighted the potential of BTN3A1 to form IgC-IgC homodimers ([@bib21]), and indeed, our modeling studies confirmed that BTN2A1 homodimers are likely to form highly equivalent IgC-IgC interactions. However, our results highlight the potential of BTN2A1 homodimer stabilization via an interchain disulphide-linkage involving a membrane-proximal cysteine residue absent in BTN2A2 and BTN3 molecules. Combined with our successful production of BTN2A1 IgV as a soluble functional monomeric domain, this suggests that BTN2A1 may form a "Y-shaped" dimer analogous to that proposed for BTN3A1 homo- and heterodimers ([@bib21], [@bib33]) and BTNL3.8 and BTNL1.6 heterodimers ([@bib17], [@bib37]). Nevertheless, an important caveat is that although our studies suggest BTN2A1 preferentially homodimerizes even when co-expressed alongside BTN3A1, conservation of residues at the IgC interface means we cannot exclude non-disulphide-stabilized IgC-IgC-mediated heterodimeric interactions with other BTN molecules, including potentially BTN2A2 or, alternatively, BTN3A2 or BTN3A3 ([@bib33]).

Importantly, we also establish a close association between BTN2A1 and BTN3A1 on target cells. While these results are consistent with those of Rigau et al., who determined co-localization of BTN2A1 and BTN3A1 to within the 10-nm resolution limit of FRET detection ([@bib25]), our immunoprecipitation approach employed a membrane-impermeable cross-linker featuring a 16-Å spacer arm, thereby suggestive of a close, possibly direct association at the cell surface. While importantly these experiments defined discrete, higher-MW species incorporating both BTN2A1 and BTN3A1, the requirement for chemical cross-linking to immunoprecipitate such complexes suggests the association is likely of relatively low affinity. Consistent with a direct interaction, our nuclear magnetic resonance (NMR) studies indicate that IgV-IgV interactions likely contribute to this *cis*-BTN2A1-BTN3A1 association and corroborate recent mutagenesis results ([@bib37]) that highlighted a critical role for residues on the CFG face of BTN3A1 or BTN3A2 IgV in P-Ag sensing. An interesting precedent for involvement of this CFG face in IgSF interactions in *cis* is provided by a recent study by Chaudhri and colleagues, who showed that PD-L1 may similarly utilize the CFG face of its IgV domain to mediate *cis*-interactions with B7.1 ([@bib2]). Notably, similar immunoprecipitation results were obtained in the presence or absence of Zol, which stimulates P-Ag accumulation in target cells, indicating that while likely essential for P-Ag sensing, BTN2A1-BTN3A1 association per se may not provide the critical molecular signal for Vγ9Vδ2 activation. Of relevance, the potential for BTN3A1 to heterodimerize with BTN3A2 or BTN3A3 and promote optimal P-Ag sensing ([@bib33]), the identical IgV domain sequences of BTN3A1 and BTN3A2, and recent mutagenesis results on BTN3A1 and BTN3A2 ([@bib37]) are important considerations in interpreting these results and suggest that BTN2A1 IgV interactions with BTN3 could involve IgV domains of different BTN3 family members.

Collectively, our results and those of [@bib25] revise current models of P-Ag sensing, many of which have previously focused on BTN3A1 as a "lone TCR ligand," and proposed either direct presentation of P-Ag by the IgV domain ([@bib34]) or "inside-out" models whereby binding of P-Ag to the intracellular BTN3A1 B30.2 domain is transmitted in some way to the extracellular region of BTN3A1, creating a TCR binding site ([@bib29], [@bib36]). Importantly, our results do not exclude the possibility of direct TCR-BTN3A1 interactions, and indeed, recent mutagenesis of BTN3A1 and BTN3A2 ([@bib37]) could be interpreted as supporting Vγ9-BTN3A1 or BTN3A2 binding using a mode similar to both Vγ4-BTNL3 and Vγ9-BTN2A1. Nor can we discount the possibility of parallel and/or sequential interaction of Vγ9 TCR with BTN2A1 or BTN3A1 IgV domains. However, the unequivocal demonstration by our study and by [@bib25] of direct Vγ9-BTN2A1 interaction, combined with lack of any compelling evidence for direct TCR-BTN3A1 or TCR-BTN3A2 interaction and finally our detection of direct BTN2A1-BTN3A1 complexes in this study, point to alternative possibilities. Taken together, these observations strongly suggest a composite ligand model of Vγ9Vδ2 recognition involving coordinate Vγ9-germline-mediated interaction with BTN2A1 alongside a CDR3-mediated interaction with a separate ligand(s). The identity of such a TCR ligand and its potential association partners at the cell surface is currently a focus of investigation. One possibility that cannot be excluded is that BTN3A1 is itself recognized in complex with BTN2A1 following P-Ag exposure, although our demonstration of constitutive BTN2A1-BTN3A1 association might argue against this; given that BTN2A1-BTN3A1 complexes occur in the absence of P-Ag, this would still require an inside-out mechanism to configure complexes for productive TCR-mediated recognition. Alternatively, it is tempting to speculate that BTN3A1 could function (potentially with facilitation by BTN3A2 or BTN3A3) to chaperone a critical additional Vγ9Vδ2 TCR ligand to the surface to be coordinately recognized as part of a BTN3A1-ligand complex in a CDR3-mediated fashion alongside BTN2A1. One prediction of this model is that such a CDR3-recognized ligand(s) is likely to be highly conserved between humans and rodents. Of note, instead of invoking direct BTN3A1 IgV interaction with the Vγ9Vδ2 TCR, this second model proposes BTN3A1 association with BTN2A1 as a mechanism of recruiting another ligand to the complex following P-Ag exposure; this would allow the Vγ9Vδ2 T cell compartment to continually survey BTN3A1-BTN2A1 complexes for the presence of a P-Ag-regulated ligand. In this context, alongside Vγ9 interaction with BTN2A1, such BTN3A1-BTN2A1 interactions most likely serve to spatially orientate BTN3A homo- or heterodimers and, following P-Ag exposure, an associated ligand, appropriately for TCR CDR3-mediated recognition. In this second composite ligand model, P-Ag binding to BTN3A1 B30.2 could regulate the strength of BTN3 association with such a ligand, and/or trafficking of such complexes to the cell surface. Further studies are required to clarify such mechanistic models, define structural features of the key interactions, address issues such as the role of BTN2A1 B30.2 domain, and establish relevance to other γδ T cell subsets, including the intestinal Vγ4 compartment.

In summary, we show that by acting as a direct ligand for the Vγ9Vδ2 TCR, BTN2A1 powerfully synergizes with BTN3A1 to potentiate P-Ag sensing. Vγ9Vδ2 T cells have to date been the primary focus of therapeutic development for γδ T cells. Understanding their mode of action should facilitate attempts to harness them therapeutically for either cell therapy or small molecule approaches.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-huBTN3 (CD277) clone 103.2Gift from Dr. Daniel OliveN/AAnti-huBTN3 (CD277) clone 20.1InvitrogenCat\# 14-2779-82; RRID: [AB_467550](nif-antibody:AB_467550){#interref70}Anti-huBTN2A1 (1C7D)MBLCat\# W005-3FITC anti-human Vδ2BD BiosciencesCat\# 562088; RRID: [AB_10892810](nif-antibody:AB_10892810){#interref75}F(ab') Donkey anti mouse IgG (H+L) R-PEJackson ImmunoresearchCat\# 715-116-151; RRID: [AB_2340799](nif-antibody:AB_2340799){#interref80}mIgG1,κ isotype clone p3.6.2.81eBiosciencesCat\#16-4714-85; RRID: [AB_470162](nif-antibody:AB_470162){#interref85}mIgG2a,κ isotype clone-eBM2aeBiosciencesCat\#16-4724-85; RRID: [AB_470165](nif-antibody:AB_470165){#interref90}Anti-HA.11 epitope tag affinity matrix (clone 16B12)BiolegendCat\#900801; RRID: [AB_2564999](nif-antibody:AB_2564999){#interref95}Purified anti-DYKDDDDK (FLAG) tag antibody (clone L5)BiolegendCat\#637301; RRID: [AB_1134266](nif-antibody:AB_1134266){#interref100}Anti-HA.11 epitope tag antibody, FITC labeled (Clone 16B12)BiolegendCat\#901507; RRID: [AB_2565058](nif-antibody:AB_2565058){#interref105}BTN2A1 rabbit polyclonal antibodySigmaCat\#HPA019208; RRID: [AB_1845492](nif-antibody:AB_1845492){#interref110}Goat anti-rabbit HRPThermoFisherCat\#G21234; RRID: [AB_2536530](nif-antibody:AB_2536530){#interref115}Goat anti-rat HRPThermoFisherCat\#A10549; RRID: [AB_2534047](nif-antibody:AB_2534047){#interref120}Purified mouse anti-human TCRγ/δ, clone 11F2BD BiosciencesCat\# 347900; RRID: [AB_400356](nif-antibody:AB_400356){#interref125}Anti-Vγ9 antibody, FITC (IMMU360)Beckman CoulterCat\#IM1463; RRID: [AB_130871](nif-antibody:AB_130871){#interref130}**Bacterial and Virus Strains**NEB 5-alphaNEBCat\# C2987HBL21 (DE3)NEBCat\# C2527H**Biological Samples**BrHPP-expanded Vγ9Vδ2 T cellsThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**HMBPPSigmaCat\#95058ZoledronateSigmaCat\#SML0223rhIL-2AiCurisCh.B.: ZA4621B/3Phusion high fidelity DNA polymeraseThermoFisher ScientificCat\#F530SIN-Fusion HD cloning KitTAKARACat\#639649TOPO TA Cloning kit for sequencingInvitrogenCat\#450071HAT Media Supplement (50x) Hybrid-MaxSigmaCat\#H0262HT Media Supplement (50x) Hybrid-MaxSigmaCat\#H0137PEG 1500RocheCat\# 10 783 641 001Histopaque-1077SigmaCat\#10711GeneArt CRISPR Nuclease (OFP reporter)InvitrogenCat\#A21174GeneArt CRISPR Nuclease (CD4 enrichment)InvitrogenCat\#A21175EcoRIThermoFisher ScientificCat\#ER0271NdeIRocheCat\# 11 040 227 001BamHIRocheCat\# 10 567 604 001BTN2A1 IgVThis paperN/ABTN2A2 IgVThis paperN/ASoluble T cell receptors (sTCRs)[@bib38]; this paperN/AStreptavidin-HRPThermoFisher ScientificCat\#21130Streptavidin-PE conjugateThermoFisher ScientificCat\#S866Streptavidin-APCThermoFisher ScientificCat\#S868Sulfo-EGS crosslinkerThermoFisher ScientificCat\#21566EZ-link Sulfo-NHS-LC biotinThermoFisher ScientificCat\#21335IodoacetamideSigmaCat\#I6125**Critical Commercial Assays**IL-2 mouse uncoated ELISA kitInvitrogenCat \# 88-7024-88IFN gamma Human uncoated ELISA kitInvitrogenCat \# 88-7316-88**Deposited Data**RNA-seq dataset of radiation hybrid clones filtered for transcribed human genesMendeley Data<https://doi.org/10.17632/ny6bxn4y9s.1>**Experimental Models: Cell Lines**293TDSMZCat\#ACC 635; RRID: CVCL_0063CHO (CHO-K1)ATCCCat\#CCL-61; RRID: CVCL_0214CHO human Chromosome 6Coriell Institute for Medical researchGM11580; RRID: CVCL_V287BW36 gal (BW)Dr. Nilabh Shastri Lab; [@bib28]N/A53/4 hybridoma Vγ9Vδ2 - MOP TCR[@bib32]N/AA23 Thymidine kinase negative Hamster fibroblast (HAT sensitive)Dr. Carol Stocking LabN/ABW 58C-CD28+[@bib11]N/A**Oligonucleotides**Primer and CRISPR Sequences in [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}N/AN/A**Recombinant DNA**pMIMgift from Dario VignaliAddgene \# 52114pMIG IIgift from Dario VignaliAddgene \# 52107pIZGift from Dr. Ingolf BerberichN/ApIHGift from Dr. Ingolf BerberichN/ApIH-FLAGThis paperN/ApET23aMerck MilliporeCat\# 69745-3pMT/BiP/V5-HisBInvitrogenCat\# V413020BTN2A1 IgV in pET23a (wild type and mutants)This paperN/ABTN2A2 IgV in pET23aThis paperN/ABTN3A1 IgV in pET23a([@bib27])N/AHuman and mouse γδTCRs in pMT/BiP/V5-HisBThis paper; [@bib38]N/A**Software and Algorithms**FlowJo version 10FlowJo<https://flowjo.co/>PyMOL version 2.0.7Schrodinger<https://pymol.org/2/>GraphPad Prism version 8.0.2GraphPad Software<https://www.graphpad.com>BIAevaluationGE Healthcare<https://www.gelifesciences.com/en/gb/shop/protein-analysis/spr-label-free-analysis>Origin 2015OriginLab<https://www.originlab.com/>CRISPR design toolInvitrogenN/AZHANG LAB[@bib33]<https://zlab.bio/guide-design-resources>CRISPR RGEN toolsThis paper<http://www.rgenome.net/>**Other**Sensor Chip CM5GE HealthcareCat\#29149604Sensor Chip NTAGE HealthcareCat\#BR100407HBS-PGE HealthcareCat\#BR100368HBS-EPGE HealthcareCat\#BR100188streptavidinSigmaCat\#S4622

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Benjamin E. Willcox (<b.willcox@bham.ac.uk>). Reagents generated in this study are available on request from the Lead Contact with a completed Materials Transfer Agreement.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

CHO, CHO-chr6, BW, A23, 53/4 hybridoma TCR transductants, and radiation hybrids (CHO Chr6 -- rodent fusion hybrids) were cultured with RPMI (GIBCO) supplemented with 10% FCS, 1 mM sodium pyruvate, 2.05 mM glutamine, 0.1 mM nonessential amino acids, 50 μM β-mercaptoethanol, penicillin (100 U/mL) and streptomycin (100 U/mL). Peripheral blood mononuclear cells isolated from healthy volunteers were also maintained as above with or without rhIL-2 (Novartis Pharma). 293T cells were maintained in DMEM (GIBCO) supplemented with 10% FCS.

Method Details {#sec4.4}
--------------

### Generation of radiation hybrids {#sec4.4.1}

CHO Chr 6 (10^6^ or 10^7^ cells) were irradiated at Faxitron CP160 (program 160 kV, 6.3 mA, 300 Gy: 60 min, 100 Gy: 20 min). The irradiated cells and fusion partner (BW or A23) were mixed at 1:1 or 1:3 ratio (irradiated cell:fusion partner) and centrifuged at 461 g for 5 min at RT. The cell pellet was gently tapped and 1 mL PEG1500 was added slowly over a minute with gentle mixing in a prewarmed water-bath. After addition of PEG, cells were resuspended in 50 mL warm serum free RPMI and incubated for 30 min, followed by centrifugation at 461 g for 5 min and careful resuspension in RPMI supplemented with 10% FCS at 10^4^ cells/mL. The cell suspension was seeded in 96 well plate flat bottom (A23 fused) or round bottom (BW fused) plates in 100 μl per well. On the following day, 100 μl of 2X HAT was added and cells were selected for two weeks. The selected clones were supplemented with HT medium and further seeded at limiting dilutions to obtain single cell clones which were tested for P-Ag mediated activation of our Vγ9Vδ2 TCR (MOP) transductants. P-Ag presentation capable and incapable clones were PCR characterized for human Chr 6 regions with primers listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

### RNAseq analysis of Radiation Hybrids {#sec4.4.2}

Knowing the differences in antigen presentation of the various radiation hybrid cell lines, we performed RNA seq to identify those human Chr 6-encoded genes that are expressed in each hybrid line. Cells were stored in TRIzol Reagent (Invitrogen) and total RNA was extracted. Sequencing libraries were produced with an Illumina Truseq RNA preparation kit as described by the supplier's protocol and were sequenced with an Illumina HiSeq4000. Sequence reads were mapped to the human genome (hg38) with STAR (version STAR_2.50a) and read counts of gene transcripts were determined using gtf file Homo_sapiens.GRCH38.84.gtf and featureCount (v1.5.0-p1). Cell lines were then compared for presence, i.e., expression, of human Chr 6 genes. To filter out reads descending from mouse or hamster cells, all fastq-files were initially mapped against the mouse genome (*Mus musculus*, version GRCm38) using STAR and the corresponding Gene Transfer Format (gtf) file (version 87). Unmapped reads and those exhibiting more than two mismatches were selected and mapped against the Chinese hamster genome (*Cricelulus griseus*, version 1). The corresponding gtf-file was downloaded from the pre-Ensembl ftp site (Cricetulus_griseus.CriGri_1.pre.gtf). Afterward, all unmapped reads and those containing more than two mismatches were again selected to finally map against the human genome (version hg38; gtf-file version 84). Only reads showing maximally one mismatch were considered as true. With the help of featureCounts, mapped reads were assigned to genomic features using the above mentioned gtf-files. The results were summarized within an Excel-file. Further gene information were extracted from BioMart (Ensembl Genes 84; ([@bib39]).

### In vitro stimulation with human Vγ9Vδ2 TCR transductants {#sec4.4.3}

For *in vitro* stimulations, 10^4^ CHO or 293T cells were seeded on day 1 with 50 μL RPMI or DMEM in a 96 well flat bottom cell culture plate and cultured over-night. On day 2, 50 μL of 5x10^4^ - 53/4 hybridoma cells expressing the human MOP Vγ9Vδ2 TCR and 100 μL of appropriate stimulant such as HMBPP, Zol, or 20.1 mAb were added to the culture and incubated for 22 h. After overnight incubation, the activation of TCR transductants was analyzed by measurement of mouse IL-2 from the supernatants of the co-cultures by ELISA (Invitrogen) as per manufacturer's protocol.

### Expansion of primary human polyclonal Vγ9Vδ2 T cells {#sec4.4.4}

Fresh peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers after obtained written informed consent in accordance with the Declaration of Helsinki and approval by the University of Würzburg institutional review board. Whole blood was layered over the Histopaque-1077 in a 50 mL falcon tube and centrifuged at 400 g for 30 min at room temperature (RT) with no acceleration and brakes. After centrifugation, the opaque interface containing PBMCs were aspirated and washed twice at 461 g for 5 min at RT. Vγ9Vδ2 T cells were expanded by cultivation of PBMCs with RPMI containing 10% FACS, 1 μM BrHPP and recombinant human IL-2 100 IU/mL (Novartis Pharma) in 10^6^ cells/mL density in a 96 well U bottom plate for 10 days with 100 μL per well. After 10 days, cells were pooled and washed twice and cultivated to rest without rhIL- 2 at 10^6^ cells/mL density in a 6-well plate. After three days, rested cells were subjected for further experiments.

### Generation of 293T *BTN2*^*−/−*^ cell lines {#sec4.4.5}

*BTN2A1* and *BTN2A2* genes were disrupted in 293T cells using CRISPR. The CRISPR sequencing targeting functional *BTN2A* genes were designed with the help of online tools mentioned in the table (software section) and sequences were cloned into GeneArt CRISPR Nuclease vector as per manufacturer's instructions. On day1, 1.5 × 10^6^ 293T cells were seeded in a 6 cm cell culture plate with DMEM medium without pyruvate (10% FCS). On day 2, cells were transfected with 5 μg of BTN2A-IgV_CRISPR cloned GeneArt CRISPR Nuclease (CD4 enrichment) Vector or BTN2A1_49FCRISPR cloned GeneArt CRISPR Nuclease (OFP Reporter) Vector or BTN2A2_343CRISPR cloned GeneArt CRISPR Nuclease (CD4 enrichment) Vector in a calcium-phosphate dependent method ([@bib40]) (CRISPR sequences are provided in [Table S2](#mmc1){ref-type="supplementary-material"}). 48 h post transfection, the highest reporter expressing (top 3%) cells were sorted and seeded at 1 cell/200 μL medium/well in 96 well plate flat bottom cell culture plate and cultivated till single cell derived clones were visible. Such clones were tested for their capacity to stimulate our 53/4 hybridoma human Vγ9Vδ2 TCR (MOP) TCR transductants in the presence of 1 μM HMBPP. The clones which exhibited loss of function were subjected to DNA isolation, followed by PCR for the amplification of genetic loci targeted by CRISPR sequences with appropriate genomic primers ([Table S2](#mmc1){ref-type="supplementary-material"}) complementary to flanking regions of CRISPR target site. The PCR products were cloned into TOPO-TA vector (Invitrogen) and the TOPO-TA clones were analyzed by sequencing for the presence of in/del mutations resulting in loss of gene mutation as shown below. 293T *BTN2*^*−/−*^ cell line harbor *BTN2A1* alleles with 10 and 16 nucleotide deletion, *BTN2A2* alleles with 1 and 10 nucleotide deletions; 293T *BTN2A1*^*−/−*^ harbors *BTN2A1* alleles with 1 nucleotide addition and 10 nucleotide deletion; 293T *BTN2A2−/−* harbors *BTN2A2* alleles with 1 nucleotide deletion.

#### CRISPR target sites and allelic phenotypes {#sec4.4.5.1}

1a) *BTN2−/−* allelic phenotype

BTN2A1 IgV CRISPR target site

2A1IgV       GCAGTGTTTGTGTATAAAGGTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  55

2A1allele1  GCAGTGTTT-------------------------------GTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  45

2A1allele2  GCA-------------------------------------------------GTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  39

              ^∗∗∗^                    ^∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗^

1b) *BTN2A2* IgV CRISPR target site

2A2IgV       GCAGTGTTTGTGTATAAGGGTGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  55

2A2allele1  GCAGTGTTTGTGTATA-GGGTGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  54

2A2allele2  GCAGTGTTTG------------------------------TGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT  45

              ^∗∗∗∗∗∗∗∗∗∗^           ^∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗^

2\) *BTN2A1*−/− allelic phenotype

2A1-49F      GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGGCCATGAA-GACGGGGGCATCCGGC  59

Allele1      GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGGCCATGAAGGACGGGGGCATCCGGC  59

Allele2      GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGG------------------------------------------GGCATCCGGC  45

              ^∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗^                 ^∗∗∗∗∗∗∗∗∗∗^

3\) *BTN2A2−/−* allelic phenotype

2A2          CAAGAAGGCAGGTCCTACGATGAGGCCATCCTACGCC-TCGTGGTGGCA  48

Allele      CAAGAAGGCAGGTCCTACGATGAGGCCATCCTACGCCCTCGTGGTGGCA  49

             ^∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗^

### Human IFNγ assay {#sec4.4.6}

293T or 293T *BTN2*^*−/−*^ cells were seeded overnight in triplicates at 2 × 10^4^ cells/well in 100 μL DMEM containing 10% FCS in a 96 well flat bottom cell culture plate with or without 25 μM Zol. Next day, DMEM with/without Zol was aspirated and cells were washed twice with PBS at RT and 2 × 10^4^ expanded Vγ9Vδ2 T cells/well in 100μL RPMI was added and cocultured for 4 h. After 4 h, supernatants were collected and frozen at −20°C, until cytokine assay was performed with human IFNγ ELISA kit (Invitrogen) was used according to the manufacturer's instructions.

### Cloning and expression of BTN2A1, BTN2A2 or mutants {#sec4.4.7}

The full length human *BTN2A1* and *BTN2A2* were amplified from the cDNA obtained from 293T cells with the help of pMIM-BTN2A1/2Fwd and pMIM-BTN2A1/2Rev primers (see [Table S2](#mmc1){ref-type="supplementary-material"}) using Phusion DNA polymerase (Thermo Scientific). The amplified BTN2A1 or BTN2A2 PCR products were cloned into EcoRI & BamHI digested pMIM or pMIG II vector via In-Fusion HD cloning kit (Takara). BTN2A1 mutants were generated by fusion of two PCR products obtaining from pMIM-BTN2A1Fwd/Mutant-Rev and Mutant-Fwd/pMIM- BTN2A1/2Rev and cloned as above. Such cloned BTN2 genes and their corresponding mutants were expressed in target cells through retroviral transduction ([@bib41]).

### Generation of FLAG/HA tagged BTN3A1 and BTN2A1 {#sec4.4.8}

For the N terminus FLAG or HA tagged proteins, FLAG or HA tag was inserted into the BamHI+EcoRI digested pIH or pIZ vector back bone with digested FLAG/HA Fwd and Rev oligonucleotide sequences with appropriate restriction sites and linker sequences flanking the FLAG/HA tag sequences. BTN3A1 and BTN2A1 full length amplicons without leader peptide were amplified either cDNA or above mentioned pMIM-BTN2A1 as template. BTN2A1-HA tagged constructed amplified with pMIM-BTN2A1 as template and pIZ-BTN2A1Fwd and BTN2A1- HA-Rev primers was cloned into pIZ vector backbone via In-Fusion-HD cloning as per manufacturer's protocol.

### Generation of Vγ9Vδ2 TCR (MOP) and mutant TCR chains {#sec4.4.9}

Vγ9Vδ2 TCR (MOP), Vδ2-R51A and Vδ2-CDR3 deletion mutant (ΔCDR3: CDR3δ sequence CACD--------YTDKLIF) TCR chains were generated as reported earlier ([@bib16], [@bib32]). Vγ9-E70A, -E70R and -E70K mutants were generated by fusion of two PCR products amplified by MOP- Vγ9 Fwd/Mut-Rev and Mut-Fwd/ MOP-Vγ9-Rev primers with pEGN-MOP-Vγ9 as template using Phusion polymerase. Such generated wild type TCR chains and mutant TCR chains were expressed in 53/4 hybridoma cells by retro-viral transduction ([@bib41]).

### Soluble protein production {#sec4.4.10}

cDNA encoding wild type BTN2A1 (S27 to V142) or BTN2A2 IgV domains (S31 to V146), or BTN2A1 IgV incorporating the described mutations, were generated as gblocks (Integrated DNA Technologies) including the sequence for a C-terminal 6x Histidine tag and cloned into the pET23a expression vector (Novagen). Proteins were overexpressed, purified and refolded as described ([@bib37]). BTN2A1 and BTN2A2 IgV domains were refolded by dilution in 100 mM Tris, 400 mM L-Arginine-HCl, 2 mM EDTA, 6.8 mM cystamine, 2.7 mM cysteamine, 0.1 mM PMSF, pH 8, overnight at 4°C. The refolding mixture was concentrated and purified by size exclusion chromatography on a Superdex-200 column (GE Healthcare) pre-equilibrated with 20 mM Tris, 150 mM NaCl, pH 8, or 20 mM Na3PO4 pH 7.4 buffer, or PBS. BTN3A1 IgV was expressed, refolded, and purified as described ([@bib27]). Soluble γδ TCRs were generated in *Drosophila* S2 cells and purified by nickel chromatography as previously described ([@bib38]). TCRs were then biotinylated via a C-terminal BirA tag.

### Flow cytometry/TCR tetramer staining {#sec4.4.11}

Flow cytometry staining of the samples were performed with the below mentioned antibodies and samples were measured on FACSCalibur or LSRII flow cytometer (BD). The expression of BTN3A1 and BTN2A1 were detected with anti-huBTN3 (CD277) clone 103.2 (gift from David Olive) and anti-huBTN2A1 clone 1C7D (MBL), followed by secondary antibody F(ab') Donkey anti mouse IgG (H+L) R-PE (Jackson Immunoresearch). mIgG1,κ isotype clone p3.6.2.81 (eBiosciences) and mIgG2a,κ isotype clone-eBM2a (eBiosciences) were used a isotype controls and were detected by above mentioned secondary antibody. N-terminal HA-tagged BTN2A1 or BTN2A2 were detected using anti-HA-FITC (Biolegend). PBMC expanded human Vγ9Vδ2 T cells were detected with FITC- conjugated anti-human Vδ2 (BD Biosciences). Biotinylated soluble Vγ9Vδ2 TCRs were tetramerized by the addition of Streptavidin-PE conjugate (ThermoFisher Scientific) at room temperature, and 1-2μg of tetramer used to stain 10^5^ cells at 4°C.

### Surface plasmon resonance {#sec4.4.12}

SPR was performed as previously described ([@bib42]) on a BIAcore3000 using streptavidin-coated CM5 chips and HBS-EP buffer (GE Healthcare). Biotinylated Vγ9 TCRs, and control Vγ2, or Vγ4 TCRs (2000-3000 RU), were captured on the Streptavidin chip. Analyte concentrations ranged from 1-200 μM.

### Immunoprecipitation, surface biotinylation, and crosslinking {#sec4.4.13}

293T cells in which the *BTN2A1* and *BTN2A2* loci have been functionally inactivated (293T *BTN2*^*−/−*^ cells), or CHO CD80^+^ cells, were transduced to overexpress HA-tagged BTN2A1 or BTN2A2, or BTN3A1, as indicated. Cells were surface biotinylated using EZ-Link Sulfo NHS-LC-biotin (ThermoFisher, 0.8mg/mL in PBS) for 30 min on ice, quenched with 20mM Tris pH 7.5 for 5 min, washed in TBS, and lysed in lysis buffer containing 1% NP40 in 20mM Tris pH 7.5, 150mM NaCl ± 10mM iodoacetamide (Sigma). HA-tagged BTN2A1 or BTN2A2 was immunoprecipitated using anti-HA resin (BioLegend). Immunoprecipitations were washed in lysis buffer and eluted in nonreducing (NR) or reducing (R) SDS sample buffer and boiled, or incubated at 37C for 5 min before separation on 4%--20% SDS-PAGE gels (BioRad). Proteins were transferred to PVDF using the BioRad TransBlot Turbo system, blocked in 3% BSA, then incubated with streptavidin-HRP (Thermo). To investigate potential association of BTN2A1 and BTN3A1 at the cell surface, CHO cells overexpressing BTN2A1-HA, FLAG-BTN3A1, or both, were treated with the soluble, membrane-impermeable crosslinker sulfo-EGS (ThermoFisher) at 0.5mM in PBS, at 4°C for 2 h. Following this, the reaction was quenched by addition of Tris pH 7.5 to 20mM. Cells were washed in TBS and lysed in 1% NP40 lysis buffer. After centrifugation to remove insoluble material, immunoprecipitation was carried out using anti-HA resin or 20.1 antibody bound to protein A Sepharose (GE Healthcare). Immunoprecipitates were run on duplicate 4%--20% gels (BioRad) and blotted with anti-BTN2A1 or anti-FLAG antibodies.

### I-TASSER modeling of BTN2A1 and BTN2A2 ectodomains {#sec4.4.14}

The ectodomain structures of BTN2A1 (residues Q29-A248) and BTN2A2 (residues Q33-M265), were generated using the I-TASSER (Iterative Threading ASSEmbly Refinement) server ([@bib45]). Briefly, the target sequences were initially threaded through the Protein Data Bank (PDB) library by LOMETS2, an online meta- threading server system for template-based protein prediction. Continuous fragments were excised from LOMETS2 alignments and structurally reassembled by replica-exchange Monte Carlo simulations. The simulation trajectories were then grouped and used as the initial state for second round I-TASSER assembly simulations. Finally, lowest energy structural models were identified and refined by fragment-guided molecular dynamic simulations to improve hydrogen-bonding contacts and omit steric clashes. Models were ranked based on their I-TASSER confidence (C) score (range −5 to +2 with a higher score correlating with a higher confidence model).

### Modeling the BTN2A1-IgV/Vγ9 complex {#sec4.4.15}

The BTN2A1-IgV/Vγ9 complex was modeled with HADDOCK ([@bib44]). BTN2A1 residues (R65, K79, R124, Y126 and E135) were classified as active in Vγ9 binding based upon the results of SPR binding experiments. 'Passively involved' residues were selected automatically. Vγ9 residues (R20, D72, E70 and E76) selected for use as ambiguous interaction restraints to drive the docking process with BTN2A1 were predicted from an initial homology model (generated by superimposing BTN2A1-IgV and Vγ9 onto the previously published BTNL3-IgV/Vγ4 complex model ([@bib17]).

### Analysis of structural modeling and mutagenesis data {#sec4.4.16}

R65 (located in the IgV domain of BTN2A1) forms a salt bridge interaction with E76 (in the Vγ9 TCR chain). This interaction is likely to be abolished by introducing Ala at this position in BTN2A1 IgV domain (R65A), consistent with abrogation of binding by the R65A mutant. The hydroxyl group of S72 (BTN2A1) is in close proximity to V58 (TCR). Juxtaposition of this polar residue (S72) with a hydrophobic residue (V58) is likely to be energetically unfavorable for binding in this region. By substituting an Ala (ie a non-polar residue) at this position, the S72A mutation is likely to introduce hydrophobic interactions with V58, consistent with enhanced binding compared to wild-type (11-15μM (S72A) versus 50μM (Wild-type)).

K79A leads to reduced binding to TCR (100μM). K79 forms a salt bridge interaction with E76 (TCR). Change to Ala will result in loss of this interaction consistent with a reduction in binding affinity. The fact that binding is not totally abolished suggests that this interaction is a not a major contributor to the binding energy. Note however that E76 also contacts R65 (see above).

R124A mutation in BTN2A1 abolishes binding to TCR. The HADDOCK model suggests that R124 forms a salt bridge interaction with E70 (Vγ9-IgV TCR) and a hydrogen bonding interaction with the hydroxyl group of T83. These interactions will be lost when introducing an Ala at this position.

Y126A abolishes binding to TCR. Y126 forms multiple hydrophobic stacking interactions with I74 (HV4 region of Vg9-IgV). In addition, the hydroxyl group of Y126 forms a hydrogen bonding interaction with T77. These will be lost upon alanine substitution.

Although Y133A is located at the interface with Vγ9, it does not mediate interactions with Vγ9 TCR residues and hence it is unsurprising that substitution to alanine does not affect binding affinity. E135 forms a salt bridge interaction with R20 (TCR). Substitution to Ala will result in a loss of this interaction, and consistent with this, E135A mutation abolishes binding to the TCR.

### NMR {#sec4.4.17}

HSQC experiments were performed at 298K on 600MHz Bruker Avance III spectrometer equipped with a 5 mm TCI cryogenically cooled triple resonance probe. Spectra were acquired using 100 μM ^1^H-^15^N-labeled BTN3A1. Experiments were processed using Topspin 3.2 (Bruker). All analysis was performed using CCPN Analysis ([@bib43]). For analysis of BTN3A1/BTN2A1 interaction, the final concentration of each protein was 100μM, and a threshold of 0.015 weighted average ppm difference was used as a cut-off to identify chemical shift perturbations in BTN3A1 residues upon BTN2A1 addition.

### Software {#sec4.4.18}

Structural figures were generated in PyMOL (version 2.0.7; Schrodinger, LLC). SPR data was analyzed in BIAevaluation (GE Healthcare) and Origin 2015 (OriginLab).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical analyses {#sec4.5.1}

Stimulation data and transcript visualization in [Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}A were calculated and depicted using GraphPad Prism. Differences between transduced and untransduced cells were tested using 2-way ANOVA and unpaired multiple t test using the Holm-Sidak method.

Data and Code Availability {#sec4.6}
--------------------------

The RNaseq data of radiation hybrid clones filtered for transcribed human genes are available at Mendeley data [https://doi.org/10.17632/ny6bxn4y9s.1](10.17632/ny6bxn4y9s.1){#intref0055}
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